Skip to main content
OpenTrials
Completed

NCT Number: NCT03336099

Assessment of the Effect of Spa Treatment on the Functional Severity of Arthrosis

Assessment of the effect of spa treatment on the functional severity of arthrosis.

Official title: Evolution of clinical state of patients with rheumatic disease on lower limbs or rachis, 6 months after spa treatment.

Primary outcome measure:

* Measuring the effect of spa treatment on functional severity of arthrosis

* Proportion of patients with a WOMAC score augmented by 9 or more, 6 months after enrollment (minimal clinically important difference)

Secondary outcome measures

* Quantitative evaluation of pain

* Comparison of mean Visual Analogue Scale (VAS) pain scale between enrollment and 6 months after * Quantitative evaluation of WOMAC

* Comparison of mean WOMAC between enrollment and 6 months after * Impact of spa treatment on the patient's metabolism

* Height and Weight (BMI calculation) * Blood pressure * Heart rate * Quality of life

* 36-Item Short Form (SF36) at enrollment, 3 months and 6 months * EuroQol 5 Dimensions (EQ5D) questionnaire at enrollment, 3 months and 6 months * Opinion of doctor and patient

* Semi-quantitative scale collected at enrollment, 3 months and 6 months * Treatment follow-up * Self-evaluation of pain

* Self-evaluation of pain with VAS pain scale every 6 week

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Thermes de Vals Les Bains

Vals-les-Bains, Ardèche, 07600, France

About this study

Arthrosis and rheumatic diseases on the whole consist in a huge and frequent public health problem, with consequences notably including the well-known pain phenomena.

Spa treatments are part of the mainstream therapeutic arsenal of non-medical treatments proposed to this kind of patients.

A recent French study estimated the direct cost of arthrosis in France to 1.6 billion euros in 2002. Half of it was attributable to hospital expenses (800 million euros). Arthrosis required 13 million consultations and drug expenses amounting to 570 million euros. These expenses were increased by 156% compared to 1993 due to the raise of the number of treated patients (+54%) and the cost for each patient (+2.5% per year). This study concerned patients with arthrosis on the lower limbs, with an significant portion of these expenses attributable to the disease.

Different thermal clinical trials of good quality have led to the recognition of spa in the treatment of chronic low back pain.

Several controlled and randomized prospective trials already evaluated the effect of spa treatment for the other main indications claimed by crenotherapy in rheumatology : chronic low back pain, coxarthrosis, hand arthrosis, fibromyalgia, rheumatoid polyarthritis, psoriatic arthritis, chronic cervicalgia.

The THERMARTHROSE study by Forestier has demonstrated the efficacy of spa treatment as a rheumatologic indication for gonarthrosis on WOMAC and VAS pain scale. Following the model of this study, the sponsor chose to use the WOMAC as the primary endpoint for the VALS study.

It has been developed by Bellamy in 1988, and it is a functional index aimed on the locomotor system.

Nowadays, the WOMAC is more used than the Lequesne index because it has better internal consistency reliability. However, complementary validation efforts were necessary to calculate the minimal clinically important difference whereas the pertinence of the Lequesne index is immediately perceptible, being purely qualitative.

With studies in thermal environment, spa treatment is a composite entity including the effect of water itself, but also kinesiotherapy, rest, education… The spa of Vals-les-Bains wishes to obtain a new therapeutic orientation: the rheumatologic orientation. According to the recommendations of the Academy of Medicine, a prolonged observation of a cohort with repeated measures is required for any spa wishing to acquire the accreditation for a new orientation.

Toward this goal, the sponsor wish to undertake a prospective study with repeated measures in order to analyze the evolution at 6 month of the clinical state of patients with a rheumatologic disease on the lower limbs or the rachis and taken over for spa treatment at Vals-les-Bains. Since rheumatologic treatments at Vals-les-Bains are not covered by the health insurance, they will not be billed to the patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with arthrosis or other rheumatic disease, located on the lower limbs or the rachis
  • Rheumatic indication for spa treatment
  • Diminution of mobility
  • Affiliation to the French social security system or equivalent
  • Available for a 6-months follow-up and an 18-days spa treatment

Exclusion criteria

  • Pregnancy, parturient or breast feeding
  • Psychiatric illness or social situation that would preclude study compliance
  • Contraindication to spa treatment
  • Predictable intolerance to thermal treatment

Treatment and study plan

Spa Treatment

Other
  • Bath with immersion shower
  • Overall shower, penetrating shower
  • Multiple local application cataplasm
  • Single local application cataplasm
  • Inhalation or collective steam bath
  • Individual physiotherapy technique

Primary outcomes

  1. Measuring the effect of spa treatment on functional severity of arthrosis

    Time frame: 6 months

    Proportion of patients with a WOMAC score augmented by 9 or more, at 6 months compared to baseline (minimal clinically important difference)

Secondary outcomes

  1. Quantitative evaluation of pain

    Time frame: at baseline, 3 and 6 months

    Comparison of mean VAS pain scale between baseline, 3 and 6 months

  2. Quantitative evaluation of WOMAC

    Time frame: at baseline, 3 and 6 months

    Comparison of mean WOMAC between baseline, 3 months and 6 months

  3. Patient's BMI

    Time frame: at baseline, 3 and 6 months

    weight and height will be combined to report BMI in kg/m2

  4. Quality of life

    Time frame: at baseline, 3 and 6 months

    SF36 questionnaire at baseline, 3 and 6 months

  5. Quality of life

    Time frame: at baseline, 3 and 6 months

    EQ5D questionnaire at baseline, 3 and 6 months

  6. Opinion of doctor and patient

    Time frame: at baseline, 3 and 6 months

    Semi-quantitative scale collected at baseline, 3 and 6 months

  7. Number of treatments prescribed

    Time frame: at baseline, 3 and 6 months

    Type of treatments prescribed at baseline, 3 and 6 months will be collected

  8. Changes in treatments prescribed

    Time frame: at baseline, 3 and 6 months

    changes in treatments prescribed at baseline, 3 and 6 months will be collected

  9. Treatments duration

    Time frame: at baseline, 3 and 6 months

    Duration of treatments prescribed at baseline, 3 and 6 months will be collected

  10. Self-evaluation of pain

    Time frame: at baseline, 1.5, 3, 4.5 and 6 months

    Self-evaluation of pain with VAS pain scale at baseline, 1.5, 3, 4.5 and 6 months

  11. patient examination

    Time frame: at baseline, 3 and 6 months

    heart rate

Sponsors and collaborators

Lead sponsor

Le Syndicat Intercommunal pour le Thermalisme et l'Environnement

Other

Collaborators

  • Floralis

Registry information

Official study title

Evolution of Clinical State of Patients With Rheumatic Disease on Lower Limbs or Rachis, 6 Months After Spa Treatment

Acronym: VALS

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Nov 8, 2017
Registry last updated
Nov 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.